Checkmate CMP-001-009

A multicenter, open-label, Phase 2 study of intratumoral CMP-001 in combination withntravenous PD-1–blocking antibody in subjects with selected types of advanced or metastatic cancer

Trial overview

Topic

Checkmate CMP-001-009

Description

This is a multicenter, open-label, Phase 2 clinical study of CMP-001 administered by IT injection in combination with an intravenous (IV) PD-1–blocking antibody in subjects with selected types of advanced or metastatic cancer with or without prior PD-1–blocking antibody treatment in one of 3 cohorts: CSCC, MCC, and TNBC

Physicians

Contact

Florida East Coast-Jacksonville

Maddie Hamilton